Results of treatment with alemtuzumab in a Spanish cohort of patients with multiple sclerosis in the real world: The RealMS study

Results of treatment with alemtuzumab in a Spanish cohort of patients with multiple sclerosis in the real world: The RealMS study

BackgroundAlemtuzumab (ALZ) is a humanized monoclonal antibody approved for the treatment of patients with highly active relapsing-remitting multiple sclerosis (RRMS) administered in two annual courses. The objective of this study was to describe the effectiveness and safety data of ALZ and to repor...

Full description

Bibliographic Details
Main Authors: Sara Eichau, Rocío López Ruiz, María Ruíz de Arcos, Juan Luis Ruiz-Peña, Guillermo Navarro, Miguel Ángel Calleja, José Luis Moreno-Amador, Julio Dotor García-Soto
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-03-01
Series:Frontiers in Neurology
Subjects:
real-world data
multiple sclerosis
alemtuzumab
disease-modifying therapy
effectiveness
safety
Online Access:https://www.frontiersin.org/articles/10.3389/fneur.2023.1112193/full

Internet

https://www.frontiersin.org/articles/10.3389/fneur.2023.1112193/full

Similar Items